Hemispherx Biopharma

The full company name is Hemispherx Biopharma Inc.

Announces new ticker symbol ‘AIM’ effective September 3, 2019 Announces new ticker symbol ‘AIM’ effective September 3, 2019

Hemispherx Biopharma, Inc. Changes Name to AIM ImmunoTech Inc.

Atara Biotherapeutics

bluebird bio

Genprex

Incyte

As our understanding of how cancer works evolves, so too are the methods that we are taking to treat the condition.

5 Immunotherapy Stocks to Keep a Close Eye On

Exec. Vice Chairman/CEO/Pres. of Hemispherx Biopharma Inc (HEB) Thomas K. Equels bought 29,404 shares of HEB on 06/21/2019 at an average price of $4.03 a share.

Hemispherx Biopharma Inc (HEB) Exec. Vice Chairman/CEO/Pres. Thomas K. Equels Bought $118,498 of Shares

Hemispherx Biopharma Inc (HEB) Exec. Vice Chairman/CEO/Pres.

Hemispherx Biopharma Inc. shares shot up on Tuesday after the firm announced significant progress in its Ampligen recurrent ovarian cancer program at the University of Pittsburgh Medical Center (UPMC).

News for Hemispherx Biopharma Stock (HEB)